Drug repurposing is in vogue, but it’s not always as easy as you think.

How will the industry shape up over the next five years?

Could a text message make all the difference in ensuring the integrity of drug products?

High quality excipients make all the difference to the drug development process. And yet, for years, excipients were often overlooked by the industry.

John McCafferty, CEO of IONTAS, explains how his company’s work in mammalian cells could bring biopharmaceuticals to market faster.

What are the consequences of allowing patients to purchase cell and gene therapies directly from hospitals?

Could harnessing the power of artificial intelligence put an end to the leading cause of sight loss in the developed world?

Healthcare, fake medicines, and the need for new antibiotics – a round-up from the UK East Africa Health Summit.

Can synergistic combinations rejuvenate existing antibiotics in the fight against antibiotic resistance?

Why are spherical nucleic acids so exciting for drug development?